nodes	percent_of_prediction	percent_of_DWPC	metapath
Moclobemide—CYP1A2—chronic obstructive pulmonary disease	0.427	1	CbGaD
Moclobemide—CYP2C19—Arformoterol—chronic obstructive pulmonary disease	0.0519	0.13	CbGbCtD
Moclobemide—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.0519	0.13	CbGbCtD
Moclobemide—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0432	0.108	CbGbCtD
Moclobemide—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0432	0.108	CbGbCtD
Moclobemide—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0407	0.102	CbGbCtD
Moclobemide—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0395	0.0988	CbGbCtD
Moclobemide—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0395	0.0988	CbGbCtD
Moclobemide—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0352	0.0881	CbGbCtD
Moclobemide—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0327	0.0819	CbGbCtD
Moclobemide—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.0218	0.0546	CbGbCtD
Moclobemide—Minaprine—SLC6A4—chronic obstructive pulmonary disease	0.000984	0.27	CrCbGaD
Moclobemide—Minaprine—HTR2A—chronic obstructive pulmonary disease	0.000756	0.208	CrCbGaD
Moclobemide—Bezafibrate—CYP1A1—chronic obstructive pulmonary disease	0.000678	0.186	CrCbGaD
Moclobemide—CYP1A2—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000531	0.0139	CbGpPWpGaD
Moclobemide—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.00053	0.0138	CbGpPWpGaD
Moclobemide—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000529	0.0138	CbGpPWpGaD
Moclobemide—MAOA—Serotonin Transporter Activity—IL1B—chronic obstructive pulmonary disease	0.000526	0.0137	CbGpPWpGaD
Moclobemide—MAOB—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000483	0.0126	CbGpPWpGaD
Moclobemide—MAOA—Oxidative Stress—HMOX1—chronic obstructive pulmonary disease	0.000483	0.0126	CbGpPWpGaD
Moclobemide—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000482	0.0126	CbGpPWpGaD
Moclobemide—MAOA—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000467	0.0122	CbGpPWpGaD
Moclobemide—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000453	0.0118	CbGpPWpGaD
Moclobemide—Haloperidol—CYP1A1—chronic obstructive pulmonary disease	0.000439	0.121	CrCbGaD
Moclobemide—MAOA—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000438	0.0114	CbGpPWpGaD
Moclobemide—MAOB—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000435	0.0114	CbGpPWpGaD
Moclobemide—MAOA—Oxidative Stress—CYP1A1—chronic obstructive pulmonary disease	0.000426	0.0111	CbGpPWpGaD
Moclobemide—Haloperidol—CYP1A2—chronic obstructive pulmonary disease	0.000424	0.116	CrCbGaD
Moclobemide—CYP2D6—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000422	0.011	CbGpPWpGaD
Moclobemide—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000412	0.0107	CbGpPWpGaD
Moclobemide—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.00041	0.00312	CcSEcCtD
Moclobemide—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000407	0.0031	CcSEcCtD
Moclobemide—Shock—Aminophylline—chronic obstructive pulmonary disease	0.000404	0.00307	CcSEcCtD
Moclobemide—Chest pain—Tiotropium—chronic obstructive pulmonary disease	0.000404	0.00307	CcSEcCtD
Moclobemide—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.000404	0.00307	CcSEcCtD
Moclobemide—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.000401	0.00305	CcSEcCtD
Moclobemide—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000395	0.003	CcSEcCtD
Moclobemide—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000391	0.00298	CcSEcCtD
Moclobemide—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000388	0.00295	CcSEcCtD
Moclobemide—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000388	0.00295	CcSEcCtD
Moclobemide—Tinnitus—Salbutamol—chronic obstructive pulmonary disease	0.000387	0.00295	CcSEcCtD
Moclobemide—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000386	0.00293	CcSEcCtD
Moclobemide—Flushing—Salbutamol—chronic obstructive pulmonary disease	0.000385	0.00293	CcSEcCtD
Moclobemide—CYP2C19—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000384	0.01	CbGpPWpGaD
Moclobemide—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000384	0.00292	CcSEcCtD
Moclobemide—Shock—Tiotropium—chronic obstructive pulmonary disease	0.000381	0.0029	CcSEcCtD
Moclobemide—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000378	0.00287	CcSEcCtD
Moclobemide—Tension—Arformoterol—chronic obstructive pulmonary disease	0.000376	0.00286	CcSEcCtD
Moclobemide—Tension—Formoterol—chronic obstructive pulmonary disease	0.000376	0.00286	CcSEcCtD
Moclobemide—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.000375	0.00285	CcSEcCtD
Moclobemide—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.000375	0.00285	CcSEcCtD
Moclobemide—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000372	0.00283	CcSEcCtD
Moclobemide—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000372	0.00283	CcSEcCtD
Moclobemide—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000371	0.00282	CcSEcCtD
Moclobemide—CYP2C19—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000369	0.00964	CbGpPWpGaD
Moclobemide—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000366	0.00278	CcSEcCtD
Moclobemide—Visual disturbance—Prednisolone—chronic obstructive pulmonary disease	0.000363	0.00276	CcSEcCtD
Moclobemide—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000361	0.00275	CcSEcCtD
Moclobemide—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000359	0.00273	CcSEcCtD
Moclobemide—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000359	0.00273	CcSEcCtD
Moclobemide—Haloperidol—HTR2A—chronic obstructive pulmonary disease	0.000358	0.0983	CrCbGaD
Moclobemide—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.000357	0.00271	CcSEcCtD
Moclobemide—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000356	0.00271	CcSEcCtD
Moclobemide—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000355	0.0027	CcSEcCtD
Moclobemide—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000355	0.0027	CcSEcCtD
Moclobemide—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000355	0.0027	CcSEcCtD
Moclobemide—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.000354	0.00269	CcSEcCtD
Moclobemide—CYP2D6—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000353	0.00922	CbGpPWpGaD
Moclobemide—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000353	0.00268	CcSEcCtD
Moclobemide—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000352	0.00268	CcSEcCtD
Moclobemide—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000352	0.00268	CcSEcCtD
Moclobemide—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000351	0.00267	CcSEcCtD
Moclobemide—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000351	0.00267	CcSEcCtD
Moclobemide—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.00035	0.00914	CbGpPWpGaD
Moclobemide—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.00035	0.00266	CcSEcCtD
Moclobemide—Paraesthesia—Tiotropium—chronic obstructive pulmonary disease	0.000348	0.00264	CcSEcCtD
Moclobemide—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000345	0.00263	CcSEcCtD
Moclobemide—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000345	0.00263	CcSEcCtD
Moclobemide—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000345	0.00262	CcSEcCtD
Moclobemide—Osteoarthritis—Prednisolone—chronic obstructive pulmonary disease	0.000344	0.00262	CcSEcCtD
Moclobemide—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000341	0.00259	CcSEcCtD
Moclobemide—CYP2D6—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00034	0.00886	CbGpPWpGaD
Moclobemide—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000339	0.00258	CcSEcCtD
Moclobemide—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000338	0.00257	CcSEcCtD
Moclobemide—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000338	0.00257	CcSEcCtD
Moclobemide—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000337	0.00879	CbGpPWpGaD
Moclobemide—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.000336	0.00255	CcSEcCtD
Moclobemide—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.000335	0.00255	CcSEcCtD
Moclobemide—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000332	0.00253	CcSEcCtD
Moclobemide—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000331	0.00252	CcSEcCtD
Moclobemide—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000331	0.00252	CcSEcCtD
Moclobemide—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000331	0.00251	CcSEcCtD
Moclobemide—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000331	0.00251	CcSEcCtD
Moclobemide—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000326	0.00248	CcSEcCtD
Moclobemide—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000326	0.00248	CcSEcCtD
Moclobemide—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000326	0.00248	CcSEcCtD
Moclobemide—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000326	0.00248	CcSEcCtD
Moclobemide—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000326	0.00248	CcSEcCtD
Moclobemide—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000326	0.00248	CcSEcCtD
Moclobemide—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000325	0.00247	CcSEcCtD
Moclobemide—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000325	0.00247	CcSEcCtD
Moclobemide—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000325	0.00247	CcSEcCtD
Moclobemide—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000324	0.00247	CcSEcCtD
Moclobemide—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000322	0.00245	CcSEcCtD
Moclobemide—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000322	0.00245	CcSEcCtD
Moclobemide—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000319	0.00243	CcSEcCtD
Moclobemide—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000319	0.00243	CcSEcCtD
Moclobemide—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000319	0.00242	CcSEcCtD
Moclobemide—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000319	0.00242	CcSEcCtD
Moclobemide—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000318	0.00242	CcSEcCtD
Moclobemide—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000318	0.00242	CcSEcCtD
Moclobemide—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000317	0.00241	CcSEcCtD
Moclobemide—MAOB—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000316	0.00825	CbGpPWpGaD
Moclobemide—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000316	0.0024	CcSEcCtD
Moclobemide—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000312	0.00237	CcSEcCtD
Moclobemide—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000308	0.00234	CcSEcCtD
Moclobemide—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000308	0.00234	CcSEcCtD
Moclobemide—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000308	0.00234	CcSEcCtD
Moclobemide—CYP1A2—Estrogen Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000307	0.00801	CbGpPWpGaD
Moclobemide—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000307	0.00801	CbGpPWpGaD
Moclobemide—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000307	0.00233	CcSEcCtD
Moclobemide—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000306	0.00233	CcSEcCtD
Moclobemide—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000305	0.00232	CcSEcCtD
Moclobemide—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000305	0.00232	CcSEcCtD
Moclobemide—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000304	0.00231	CcSEcCtD
Moclobemide—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000301	0.00229	CcSEcCtD
Moclobemide—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.0003	0.00228	CcSEcCtD
Moclobemide—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000292	0.00222	CcSEcCtD
Moclobemide—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000292	0.00222	CcSEcCtD
Moclobemide—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00029	0.00221	CcSEcCtD
Moclobemide—Shock—Salbutamol—chronic obstructive pulmonary disease	0.00029	0.00221	CcSEcCtD
Moclobemide—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.00219	CcSEcCtD
Moclobemide—CYP2C19—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000285	0.00744	CbGpPWpGaD
Moclobemide—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000285	0.00217	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000285	0.00217	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000285	0.00217	CcSEcCtD
Moclobemide—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000283	0.00215	CcSEcCtD
Moclobemide—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000283	0.00215	CcSEcCtD
Moclobemide—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000281	0.00214	CcSEcCtD
Moclobemide—CYP2C19—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000279	0.00728	CbGpPWpGaD
Moclobemide—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000279	0.00212	CcSEcCtD
Moclobemide—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000279	0.00212	CcSEcCtD
Moclobemide—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000279	0.00212	CcSEcCtD
Moclobemide—MAOB—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000278	0.00726	CbGpPWpGaD
Moclobemide—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000278	0.00211	CcSEcCtD
Moclobemide—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000278	0.00211	CcSEcCtD
Moclobemide—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000277	0.00211	CcSEcCtD
Moclobemide—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000276	0.0021	CcSEcCtD
Moclobemide—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000275	0.00209	CcSEcCtD
Moclobemide—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000275	0.00209	CcSEcCtD
Moclobemide—MAOB—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000275	0.00718	CbGpPWpGaD
Moclobemide—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000275	0.00209	CcSEcCtD
Moclobemide—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000274	0.00208	CcSEcCtD
Moclobemide—MAOA—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000273	0.00713	CbGpPWpGaD
Moclobemide—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000272	0.00207	CcSEcCtD
Moclobemide—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000271	0.00206	CcSEcCtD
Moclobemide—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000269	0.00205	CcSEcCtD
Moclobemide—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000269	0.00205	CcSEcCtD
Moclobemide—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000269	0.00205	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000269	0.00204	CcSEcCtD
Moclobemide—CYP2C19—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000268	0.007	CbGpPWpGaD
Moclobemide—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000267	0.00203	CcSEcCtD
Moclobemide—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000267	0.00203	CcSEcCtD
Moclobemide—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000267	0.00203	CcSEcCtD
Moclobemide—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000265	0.00202	CcSEcCtD
Moclobemide—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000264	0.00201	CcSEcCtD
Moclobemide—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000263	0.002	CcSEcCtD
Moclobemide—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000262	0.00685	CbGpPWpGaD
Moclobemide—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000262	0.002	CcSEcCtD
Moclobemide—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000261	0.00199	CcSEcCtD
Moclobemide—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.00026	0.00678	CbGpPWpGaD
Moclobemide—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.00026	0.00198	CcSEcCtD
Moclobemide—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000259	0.00197	CcSEcCtD
Moclobemide—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000259	0.00197	CcSEcCtD
Moclobemide—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000258	0.00196	CcSEcCtD
Moclobemide—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000257	0.00196	CcSEcCtD
Moclobemide—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000257	0.00196	CcSEcCtD
Moclobemide—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000257	0.00196	CcSEcCtD
Moclobemide—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000257	0.0067	CbGpPWpGaD
Moclobemide—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000256	0.00195	CcSEcCtD
Moclobemide—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000256	0.00195	CcSEcCtD
Moclobemide—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000255	0.00194	CcSEcCtD
Moclobemide—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000255	0.00194	CcSEcCtD
Moclobemide—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000254	0.00664	CbGpPWpGaD
Moclobemide—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000254	0.00193	CcSEcCtD
Moclobemide—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000252	0.00192	CcSEcCtD
Moclobemide—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00025	0.0019	CcSEcCtD
Moclobemide—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.00025	0.0019	CcSEcCtD
Moclobemide—CYP1A2—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.00025	0.00651	CbGpPWpGaD
Moclobemide—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.00189	CcSEcCtD
Moclobemide—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000248	0.00189	CcSEcCtD
Moclobemide—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000247	0.00188	CcSEcCtD
Moclobemide—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000247	0.00188	CcSEcCtD
Moclobemide—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000247	0.00644	CbGpPWpGaD
Moclobemide—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000246	0.00187	CcSEcCtD
Moclobemide—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000245	0.00639	CbGpPWpGaD
Moclobemide—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000244	0.00186	CcSEcCtD
Moclobemide—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000244	0.00186	CcSEcCtD
Moclobemide—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000244	0.00185	CcSEcCtD
Moclobemide—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000243	0.00185	CcSEcCtD
Moclobemide—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000243	0.00185	CcSEcCtD
Moclobemide—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000243	0.00184	CcSEcCtD
Moclobemide—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000242	0.00184	CcSEcCtD
Moclobemide—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000242	0.00184	CcSEcCtD
Moclobemide—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000241	0.00184	CcSEcCtD
Moclobemide—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000239	0.00182	CcSEcCtD
Moclobemide—CYP1A2—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000237	0.00617	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—CHRNA5—chronic obstructive pulmonary disease	0.000235	0.00612	CbGpPWpGaD
Moclobemide—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000234	0.00178	CcSEcCtD
Moclobemide—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00177	CcSEcCtD
Moclobemide—MAOB—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000231	0.00603	CbGpPWpGaD
Moclobemide—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00023	0.00175	CcSEcCtD
Moclobemide—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.00023	0.00175	CcSEcCtD
Moclobemide—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000229	0.00174	CcSEcCtD
Moclobemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000229	0.00598	CbGpPWpGaD
Moclobemide—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000224	0.00171	CcSEcCtD
Moclobemide—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000224	0.00171	CcSEcCtD
Moclobemide—CYP2C19—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000221	0.00577	CbGpPWpGaD
Moclobemide—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000221	0.00168	CcSEcCtD
Moclobemide—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000221	0.00168	CcSEcCtD
Moclobemide—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00022	0.00167	CcSEcCtD
Moclobemide—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000218	0.00166	CcSEcCtD
Moclobemide—CYP1A2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000217	0.00567	CbGpPWpGaD
Moclobemide—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000217	0.00165	CcSEcCtD
Moclobemide—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000214	0.00163	CcSEcCtD
Moclobemide—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000214	0.00163	CcSEcCtD
Moclobemide—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000212	0.00161	CcSEcCtD
Moclobemide—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000209	0.00159	CcSEcCtD
Moclobemide—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000209	0.00546	CbGpPWpGaD
Moclobemide—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000209	0.00159	CcSEcCtD
Moclobemide—CYP2C19—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000207	0.00541	CbGpPWpGaD
Moclobemide—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000207	0.00157	CcSEcCtD
Moclobemide—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000207	0.00157	CcSEcCtD
Moclobemide—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000203	0.00531	CbGpPWpGaD
Moclobemide—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000202	0.00154	CcSEcCtD
Moclobemide—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000202	0.00154	CcSEcCtD
Moclobemide—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000199	0.00151	CcSEcCtD
Moclobemide—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000199	0.00151	CcSEcCtD
Moclobemide—MAOA—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000198	0.00518	CbGpPWpGaD
Moclobemide—Rash—Formoterol—chronic obstructive pulmonary disease	0.000197	0.0015	CcSEcCtD
Moclobemide—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000197	0.0015	CcSEcCtD
Moclobemide—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000197	0.0015	CcSEcCtD
Moclobemide—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000197	0.0015	CcSEcCtD
Moclobemide—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000196	0.00149	CcSEcCtD
Moclobemide—Headache—Formoterol—chronic obstructive pulmonary disease	0.000196	0.00149	CcSEcCtD
Moclobemide—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000195	0.00149	CcSEcCtD
Moclobemide—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000195	0.00148	CcSEcCtD
Moclobemide—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000195	0.00148	CcSEcCtD
Moclobemide—Rash—Montelukast—chronic obstructive pulmonary disease	0.000193	0.00147	CcSEcCtD
Moclobemide—MAOB—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000193	0.00503	CbGpPWpGaD
Moclobemide—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000193	0.00147	CcSEcCtD
Moclobemide—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000192	0.00146	CcSEcCtD
Moclobemide—MAOA—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000192	0.00502	CbGpPWpGaD
Moclobemide—Headache—Montelukast—chronic obstructive pulmonary disease	0.000192	0.00146	CcSEcCtD
Moclobemide—MAOA—Transmission across Chemical Synapses—CHRNA3—chronic obstructive pulmonary disease	0.000191	0.00499	CbGpPWpGaD
Moclobemide—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000191	0.00497	CbGpPWpGaD
Moclobemide—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000188	0.00143	CcSEcCtD
Moclobemide—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000187	0.00142	CcSEcCtD
Moclobemide—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.00141	CcSEcCtD
Moclobemide—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000186	0.00141	CcSEcCtD
Moclobemide—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000186	0.00141	CcSEcCtD
Moclobemide—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000186	0.00141	CcSEcCtD
Moclobemide—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000186	0.00141	CcSEcCtD
Moclobemide—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.00141	CcSEcCtD
Moclobemide—CYP2C19—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000185	0.00481	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000183	0.00477	CbGpPWpGaD
Moclobemide—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000182	0.00139	CcSEcCtD
Moclobemide—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000182	0.00138	CcSEcCtD
Moclobemide—MAOA—Neuronal System—CHRNA5—chronic obstructive pulmonary disease	0.00018	0.00469	CbGpPWpGaD
Moclobemide—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000179	0.00136	CcSEcCtD
Moclobemide—MAOB—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000177	0.00462	CbGpPWpGaD
Moclobemide—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000176	0.00134	CcSEcCtD
Moclobemide—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000175	0.00133	CcSEcCtD
Moclobemide—MAOA—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000175	0.00456	CbGpPWpGaD
Moclobemide—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000174	0.00133	CcSEcCtD
Moclobemide—MAOA—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000173	0.00453	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000173	0.0045	CbGpPWpGaD
Moclobemide—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000172	0.0045	CbGpPWpGaD
Moclobemide—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000172	0.00131	CcSEcCtD
Moclobemide—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000168	0.00439	CbGpPWpGaD
Moclobemide—MAOB—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000168	0.00438	CbGpPWpGaD
Moclobemide—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000166	0.00127	CcSEcCtD
Moclobemide—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000165	0.00126	CcSEcCtD
Moclobemide—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000164	0.00124	CcSEcCtD
Moclobemide—CYP2C19—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000163	0.00426	CbGpPWpGaD
Moclobemide—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000162	0.00421	CbGpPWpGaD
Moclobemide—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000161	0.00122	CcSEcCtD
Moclobemide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000159	0.00416	CbGpPWpGaD
Moclobemide—CYP2C19—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000157	0.00411	CbGpPWpGaD
Moclobemide—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000153	0.00116	CcSEcCtD
Moclobemide—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000152	0.00116	CcSEcCtD
Moclobemide—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.00015	0.00391	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000149	0.00388	CbGpPWpGaD
Moclobemide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000147	0.00383	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—CHRNA3—chronic obstructive pulmonary disease	0.000147	0.00383	CbGpPWpGaD
Moclobemide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000145	0.00379	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	0.000145	0.00379	CbGpPWpGaD
Moclobemide—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000145	0.00378	CbGpPWpGaD
Moclobemide—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000143	0.00374	CbGpPWpGaD
Moclobemide—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000142	0.00108	CcSEcCtD
Moclobemide—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.00014	0.00106	CcSEcCtD
Moclobemide—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000139	0.00106	CcSEcCtD
Moclobemide—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000138	0.00105	CcSEcCtD
Moclobemide—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000136	0.00103	CcSEcCtD
Moclobemide—MAOB—Metabolism—APIP—chronic obstructive pulmonary disease	0.000135	0.00353	CbGpPWpGaD
Moclobemide—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000135	0.00103	CcSEcCtD
Moclobemide—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000134	0.00102	CcSEcCtD
Moclobemide—CYP2C19—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000134	0.0035	CbGpPWpGaD
Moclobemide—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000132	0.00101	CcSEcCtD
Moclobemide—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.00013	0.000989	CcSEcCtD
Moclobemide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000129	0.00337	CbGpPWpGaD
Moclobemide—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000128	0.000976	CcSEcCtD
Moclobemide—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000128	0.000972	CcSEcCtD
Moclobemide—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000127	0.00332	CbGpPWpGaD
Moclobemide—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000964	CcSEcCtD
Moclobemide—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000122	0.00319	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	0.000121	0.00316	CbGpPWpGaD
Moclobemide—Shock—Prednisone—chronic obstructive pulmonary disease	0.000121	0.00092	CcSEcCtD
Moclobemide—MAOA—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.00012	0.00314	CbGpPWpGaD
Moclobemide—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.00012	0.000913	CcSEcCtD
Moclobemide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000119	0.0031	CbGpPWpGaD
Moclobemide—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000904	CcSEcCtD
Moclobemide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000118	0.00308	CbGpPWpGaD
Moclobemide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000116	0.00302	CbGpPWpGaD
Moclobemide—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000114	0.00298	CbGpPWpGaD
Moclobemide—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000112	0.000852	CcSEcCtD
Moclobemide—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000112	0.000851	CcSEcCtD
Moclobemide—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000112	0.00291	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000112	0.00291	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	0.000112	0.00291	CbGpPWpGaD
Moclobemide—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000846	CcSEcCtD
Moclobemide—MAOA—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	0.000111	0.0029	CbGpPWpGaD
Moclobemide—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.00011	0.00084	CcSEcCtD
Moclobemide—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.00011	0.00287	CbGpPWpGaD
Moclobemide—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	0.000109	0.00284	CbGpPWpGaD
Moclobemide—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000108	0.000823	CcSEcCtD
Moclobemide—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000107	0.000813	CcSEcCtD
Moclobemide—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.000812	CcSEcCtD
Moclobemide—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000107	0.000811	CcSEcCtD
Moclobemide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000107	0.00278	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000106	0.00278	CbGpPWpGaD
Moclobemide—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000806	CcSEcCtD
Moclobemide—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.000806	CcSEcCtD
Moclobemide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000106	0.00276	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	0.000105	0.00275	CbGpPWpGaD
Moclobemide—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000105	0.00274	CbGpPWpGaD
Moclobemide—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000105	0.0008	CcSEcCtD
Moclobemide—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000104	0.00273	CbGpPWpGaD
Moclobemide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000104	0.00272	CbGpPWpGaD
Moclobemide—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000771	CcSEcCtD
Moclobemide—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000101	0.000765	CcSEcCtD
Moclobemide—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.000765	CcSEcCtD
Moclobemide—Urticaria—Prednisone—chronic obstructive pulmonary disease	9.77e-05	0.000743	CcSEcCtD
Moclobemide—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	9.72e-05	0.000739	CcSEcCtD
Moclobemide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	9.39e-05	0.00245	CbGpPWpGaD
Moclobemide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	9.03e-05	0.00236	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	8.95e-05	0.00234	CbGpPWpGaD
Moclobemide—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	8.91e-05	0.00232	CbGpPWpGaD
Moclobemide—Asthenia—Prednisone—chronic obstructive pulmonary disease	8.82e-05	0.000671	CcSEcCtD
Moclobemide—MAOB—Metabolism—GC—chronic obstructive pulmonary disease	8.71e-05	0.00227	CbGpPWpGaD
Moclobemide—Pruritus—Prednisone—chronic obstructive pulmonary disease	8.7e-05	0.000662	CcSEcCtD
Moclobemide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.64e-05	0.00225	CbGpPWpGaD
Moclobemide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.56e-05	0.00223	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—APIP—chronic obstructive pulmonary disease	8.48e-05	0.00221	CbGpPWpGaD
Moclobemide—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	8.41e-05	0.00064	CcSEcCtD
Moclobemide—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	8.26e-05	0.00216	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	8.17e-05	0.00213	CbGpPWpGaD
Moclobemide—Dizziness—Prednisone—chronic obstructive pulmonary disease	8.13e-05	0.000618	CcSEcCtD
Moclobemide—MAOB—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.1e-05	0.00211	CbGpPWpGaD
Moclobemide—Vomiting—Prednisone—chronic obstructive pulmonary disease	7.82e-05	0.000595	CcSEcCtD
Moclobemide—Rash—Prednisone—chronic obstructive pulmonary disease	7.75e-05	0.00059	CcSEcCtD
Moclobemide—Dermatitis—Prednisone—chronic obstructive pulmonary disease	7.75e-05	0.000589	CcSEcCtD
Moclobemide—Headache—Prednisone—chronic obstructive pulmonary disease	7.7e-05	0.000586	CcSEcCtD
Moclobemide—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	7.63e-05	0.00199	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.6e-05	0.00198	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.53e-05	0.00197	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.51e-05	0.00196	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.45e-05	0.00194	CbGpPWpGaD
Moclobemide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.32e-05	0.00191	CbGpPWpGaD
Moclobemide—Nausea—Prednisone—chronic obstructive pulmonary disease	7.3e-05	0.000556	CcSEcCtD
Moclobemide—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	7.01e-05	0.00183	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.87e-05	0.00179	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.77e-05	0.00177	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	6.57e-05	0.00172	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.44e-05	0.00168	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.36e-05	0.00166	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.32e-05	0.00165	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	6.31e-05	0.00165	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.26e-05	0.00163	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.23e-05	0.00163	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	6.18e-05	0.00161	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.18e-05	0.00161	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.81e-05	0.00152	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.73e-05	0.00149	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.65e-05	0.00147	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.62e-05	0.00147	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GC—chronic obstructive pulmonary disease	5.46e-05	0.00143	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	5.34e-05	0.00139	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.3e-05	0.00138	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.27e-05	0.00137	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.26e-05	0.00137	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	5.23e-05	0.00136	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.22e-05	0.00136	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.2e-05	0.00136	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.19e-05	0.00135	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.15e-05	0.00134	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.08e-05	0.00133	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.99e-05	0.0013	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.92e-05	0.00128	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.84e-05	0.00126	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	4.8e-05	0.00125	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.8e-05	0.00125	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.77e-05	0.00125	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.76e-05	0.00124	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.73e-05	0.00124	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	4.71e-05	0.00123	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	4.71e-05	0.00123	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GCLC—chronic obstructive pulmonary disease	4.7e-05	0.00123	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.59e-05	0.0012	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	4.58e-05	0.00119	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.55e-05	0.00119	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.53e-05	0.00118	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4.53e-05	0.00118	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.49e-05	0.00117	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	4.48e-05	0.00117	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	4.48e-05	0.00117	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.46e-05	0.00116	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.4e-05	0.00115	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CTGF—chronic obstructive pulmonary disease	4.29e-05	0.00112	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.1e-05	0.00107	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.04e-05	0.00106	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	4.01e-05	0.00105	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.95e-05	0.00103	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.89e-05	0.00101	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.83e-05	0.001	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	3.69e-05	0.000964	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	3.69e-05	0.000963	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	3.66e-05	0.000955	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.3e-05	0.000861	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.25e-05	0.000849	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	3.13e-05	0.000816	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.03e-05	0.000791	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.99e-05	0.000779	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GCLC—chronic obstructive pulmonary disease	2.95e-05	0.00077	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.87e-05	0.00075	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.86e-05	0.000747	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CTGF—chronic obstructive pulmonary disease	2.69e-05	0.000703	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.66e-05	0.000694	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.64e-05	0.000688	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.61e-05	0.000681	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	2.59e-05	0.000675	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.48e-05	0.000647	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.45e-05	0.000638	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.42e-05	0.000633	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.4e-05	0.000628	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.4e-05	0.000627	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.38e-05	0.000621	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	2.36e-05	0.000615	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.23e-05	0.000582	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.21e-05	0.000577	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.19e-05	0.000572	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.07e-05	0.000541	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.07e-05	0.00054	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.04e-05	0.000533	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	2.02e-05	0.000526	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—ALB—chronic obstructive pulmonary disease	1.95e-05	0.00051	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.92e-05	0.0005	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.9e-05	0.000496	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.87e-05	0.000489	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—NOS3—chronic obstructive pulmonary disease	1.87e-05	0.000487	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.8e-05	0.00047	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.75e-05	0.000456	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.49e-05	0.00039	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.41e-05	0.000369	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	1.4e-05	0.000364	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.3e-05	0.00034	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.3e-05	0.000339	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.29e-05	0.000336	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.28e-05	0.000335	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	1.27e-05	0.000333	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.27e-05	0.000332	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—ALB—chronic obstructive pulmonary disease	1.23e-05	0.00032	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.19e-05	0.00031	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.17e-05	0.000306	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.17e-05	0.000306	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—NOS3—chronic obstructive pulmonary disease	1.17e-05	0.000306	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.16e-05	0.000303	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.1e-05	0.000287	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.09e-05	0.000284	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.08e-05	0.000282	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.07e-05	0.000279	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.01e-05	0.000265	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	9.93e-06	0.000259	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.79e-06	0.000256	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.66e-06	0.000252	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.01e-06	0.000235	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	9e-06	0.000235	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.93e-06	0.000233	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.88e-06	0.000232	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.81e-06	0.00023	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.53e-06	0.000223	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.28e-06	0.000216	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.21e-06	0.000214	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.85e-06	0.000205	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.78e-06	0.000203	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.63e-06	0.000199	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.53e-06	0.000196	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.01e-06	0.000183	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.65e-06	0.000173	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	5.8e-06	0.000151	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	5.55e-06	0.000145	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	5.33e-06	0.000139	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	5.29e-06	0.000138	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	5.1e-06	0.000133	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	5.06e-06	0.000132	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	4.52e-06	0.000118	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	4.32e-06	0.000113	CbGpPWpGaD
